Stacking Protocol: Thymosin Alpha-1 + Thymosin Beta-4 + BPC-157 + GH Secretagogues + SS-31
Dr. Yurth's personal longevity peptide stack includes Thymosin Alpha-1, Thymosin Beta-4, BPC-157, growth hormone secretagogues, and SS-31, each serving a distinct physiological role (immune, healing, GH axis, and mitochondrial support respectively). BPC-157 is used relatively consistently while the others are cycled, with GH secretagogues specifically avoided in winter. No dosages are provided for any component in this excerpt.
Stacking Protocol: Thymosin Alpha-1 + Thymosin Beta-4 + BPC-157 + SS-31 + GH Secretagogues
Dr. Yurth's personal longevity peptide stack includes Thymosin Alpha-1, Thymosin Beta-4, BPC-157, SS-31, and unspecified growth hormone secretagogues. BPC-157 is used consistently while the others are cycled seasonally. The stack is designed to address immune decline, mitochondrial dysfunction, orthopedic repair, and GH axis support simultaneously.
Thymosin Alpha-1 Use for Thymic Replacement
Thymosin Alpha-1 is used by Dr. Yurth as part of a thymic peptide replacement strategy to compensate for age-related thymic involution. It is cycled rather than used continuously. No specific dosage or frequency is mentioned in this excerpt.
Thymic Peptides as the Most Critical Longevity Intervention
Dr. Yurth identifies thymic peptides as the single most critical category in her longevity protocol, citing the near-complete involution of the thymus gland by middle age. She uses both Thymosin Alpha-1 and Thymosin Beta-4 specifically to replace the peptides the thymus can no longer produce. She notes these cannot be adequately replaced through diet alone.
Circannual Rhythm-Based Peptide Cycling Protocol
Dr. Yurth advocates cycling peptides in alignment with circannual (seasonal) biological rhythms, arguing the body has natural phases of growth and hibernation. Winter is described as a hibernation phase where growth-promoting peptides and hormones should not be pushed to high levels. This cycling approach is presented as a core principle of her longevity protocol.
Peptide and GLP-1 Tools Require Foundation Repair First for Full Efficacy
A key mechanistic claim in the video is that peptide-based tools and GLP-1 agents cannot reach their full anti-inflammatory potential if underlying gut permeability and nervous system dysregulation are not addressed first. The sequencing principle described is: repair the foundation (gut, nutrients, dietary triggers, nervous system) first, then introduce advanced metabolic and peptide tools to amplify what is already working. This is presented as the differentiating factor between a comprehensive protocol and simply administering a single peptide.
Multi-Peptide Stack for Autoimmune Root Cause Protocol
Dr. Jones describes a comprehensive stacked protocol combining oral BPC-157 + KPV (gut lining), Thymosin Alpha-1 (immune balancing), and Larazotide (gut barrier) alongside Low Dose Naltrexone as a coordinated multi-tool approach to autoimmune remission. Each tool is assigned a specific mechanistic job within the stack, and the speaker emphasizes that none of these tools works in isolation. The protocol is presented as requiring medical supervision with ongoing lab monitoring.
Thymosin Alpha-1 and Thymosin Beta (Thymus Peptides) for Immune System Rebalancing
Dr. Jones references 'Thymus and Alpha 1' (likely Thymosin Alpha-1 and a related thymic peptide) as tools to help rebalance an immune system that has 'lost its footing' in autoimmune disease. The explicit framing is immune balancing rather than immune suppression, distinguishing this approach from conventional immunosuppressive biologics. No dosages or administration routes are specified in the transcript.
Multi-Peptide Stack for Autoimmune Root-Cause Protocol
The speaker outlines a comprehensive stacked protocol combining multiple peptides alongside low-dose naltrexone, each assigned a specific mechanistic role: oral BPC-157 + KPV for gut lining, Thymosin Alpha-1 + Thymosin Beta for immune balancing, and Larazotide for barrier repair. The stack is described as sequenced and supervised, with the explicit warning that no single tool works in isolation. The protocol is positioned as complementary to — not replacing — conventional autoimmune medications. No dosages are provided for any component.
Thymosin Alpha-1 and Thymosin Beta (Thymus Peptides) for Immune System Balancing
The speaker references 'Thymus and alpha 1' (interpreted as Thymosin Beta and Thymosin Alpha-1) as tools to help rebalance an immune system that has 'lost its footing' in autoimmune disease. The explicit framing is immune balancing rather than immune suppression, distinguishing this approach from conventional immunosuppressive biologics. No dosages or frequencies are provided. This is presented as one component of a multi-tool protocol stack.
Mechanistic Differentiation: Thymosin Alpha-1 vs. Thymosin Beta-4 — Same Family, Different Roles
Despite sharing a naming convention and peptide family classification, Thymosin Alpha-1 and Thymosin Beta-4 serve fundamentally different physiological roles — immune modulation versus tissue repair, respectively. The speaker emphasizes the importance of matching the specific peptide to the specific underlying mechanism of a patient's condition, framing this as the distinction between trend-based and targeted care. No dosages, stacking protocols, or safety warnings are discussed.
Clinical Indication Matching: TA1 for Immune Dysfunction
The speaker provides a clinical decision framework suggesting TA1 as the appropriate choice when a patient presents with immune dysfunction, recurrent infections, or immune suppression. No specific dosing protocols or treatment durations are provided.
Thymosin Alpha-1 (TA1) Primary Mechanism: Immune Modulation
Thymosin Alpha-1 (TA1) is described as primarily an immune-modulating peptide. It enhances T-cell function and supports immune resilience. The speaker frames it as providing 'immune system intelligence' rather than a broad immune boost.
Thymalin vs. Thymosin Alpha-1: Evidence Quality Comparison and Consumer Warning
The speaker warns that Thymalin and Thymosin Alpha-1 are frequently and incorrectly used interchangeably, despite representing fundamentally different categories of evidence. Thymosin Alpha-1 is characterized as a well-validated compound with robust independent clinical data, while Thymalin is described as a crude extract with variable composition and no independent validation outside its creators. Consumers are advised to understand this distinction before purchasing either compound.
Peptide Protocol Optimization as Distinct Specialty Within Multi-Disciplinary Psoriasis Care
The speaker describes a clinical model where peptide protocol optimization is handled as a distinct specialty alongside functional medicine, with Dr. Jones focusing specifically on peptides and Dr. Allen managing the broader functional medicine protocol. This division of expertise is presented as a differentiator from standard dermatology or standalone peptide clinics. The 'Restore Blueprint' is described as a 12-month protocol integrating baseline labs, personalized nutrition, supplements, and peptide optimization. This context is relevant for understanding how the peptide findings in this video are applied clinically.
Thymosin Alpha-1 Mechanism: Immune System Regulation to Reduce False-Alarm Inflammatory Signaling
Thymosin Alpha-1 is mechanistically described as acting like an immune system 'dispatcher,' helping to normalize dysregulated immune signaling that characterizes autoimmune conditions like psoriasis. The analogy used is that chronic inflammation involves a fire department responding to false alarms continuously — Thymosin Alpha-1 is framed as helping to correct this misfiring dispatch process. It is positioned as a supporting layer within a multi-peptide stack rather than a primary intervention. No dosage, frequency, or route of administration is specified.
Peptides as Amplifiers Within a Foundation-First Framework, Not Standalone Treatments
The speaker explicitly frames peptides as 'amplifiers' that work best only after foundational systems (gut health, inflammation, nutrients, dietary triggers, nervous system) have been addressed. This is described as a 'foundation first' philosophy, meaning peptides are not positioned as replacements for lifestyle and dietary interventions but as tools that enhance outcomes when layered on top of a corrected physiological foundation. This framing is a key safety and efficacy caveat for the entire peptide protocol discussed.
BPC-KPV + Thymosin Alpha-1 Combination Stack for Psoriasis
The speaker references a specific multi-peptide stacking protocol combining BPC-KPV with Thymosin Alpha-1 as part of their clinic's psoriasis treatment approach. This stack is described as being optimized alongside LDN (low-dose naltrexone) within a broader 'Restore Blueprint' protocol overseen by both a functional medicine doctor and a peptide specialist. The speaker teases a dedicated video covering exact dosing, stacking rationale, and observed timelines. No specific dosages are disclosed in this video.
Thymosin Alpha-1 as Immune Modulator in Autoimmune Psoriasis Protocol
Thymosin Alpha-1 is described as a peptide layered into the comprehensive stack specifically for autoimmune patients, including those with psoriasis. The speaker uses the metaphor of a 'dispatcher' to describe its mechanism — helping to regulate immune signaling so the immune system stops sending inflammatory responses to false alarms. It is explicitly noted as a component of a broader protocol rather than a standalone solution. No dosages or frequencies are provided.
Integrated autoimmune protocol: root cause + peptides + medical oversight
Dr. Jones outlines a three-pillar protocol for autoimmune conditions: (1) root cause functional medicine addressing gut, inflammation, nutrients, diet, and nervous system; (2) advanced tools including low-dose naltrexone, anti-inflammatory diet, and therapeutic peptides (BPC-157, KPV, Larazotide, Thymosin Alpha-1, GLP-1s); (3) medical oversight. He emphasizes that most programs only offer one or two of these pieces, and all three are needed for success.
Thymosin Alpha-1 as immune modulating peptide for autoimmune conditions
Dr. Jones mentions Thymosin Alpha-1 as an immune modulating peptide used in specific clinical settings as part of an advanced autoimmune treatment protocol. He describes it alongside other advanced tools layered on top of foundational root-cause interventions. No dosage or specific protocol details are provided.
Full EBV peptide protocol stack — TA1, KPV, SS-31, MOTS-c with supplements
The complete EBV protocol combines four peptides with nutritional support: Thymosin Alpha-1 (1 mg 2x/week, 12 weeks) for T-cell retraining, KPV (400 mcg 2x/day) for inflammatory cytokine suppression, SS-31 + MOTS-c (stacked) for mitochondrial repair. Supplements include monolaurin (titrate 500 mg to 2-3 g/day), L-lysine (2-3 g/day in 3 doses), selenium (200 mcg/day), and DGL (600 mg/day). A 2022 study (Prusty, Viruses) showed combination antiviral + immune-supportive therapy achieved 67% viral load reduction and 71% symptom improvement sustained at 12-month follow-up.
IM Route Preferred for Faster Peptide Absorption in Acute Viral Cases
Speaker specifically chose intramuscular (IM) administration for Thymosin Alpha-1, LL-37, and BPC-157 rather than subcutaneous, stating the rationale was faster absorption needed in active viral suppression cases. KPV was the exception, administered subcutaneously.
Complete HSV Peptide + Supplement Stack Protocol
Complete protocol combining immune retraining (Thymosin Alpha-1 IM 2x/week, LL-37 IM daily), direct antivirals (Monolaurin 3g/day, L-Lysine 3g/day in 3 divided doses), anti-inflammatory control (KPV 300-400mcg subQ daily), nerve repair (BPC-157 IM daily), and nutritional restoration (Magnesium glycinate 400mg, Zinc 30mg, Vitamin D3 5000IU + K2 200mcg, Selenium 200mcg, NAC 600mg 2x/day). Patient achieved zero outbreaks in 90 days after 8 years of monthly outbreaks.